ADCs in HER2-negative Metastatic Breast Cancer

Belgian treatment landscape and interactive case studies

LIVE WEBINAR Thursday 12 June 2025 - 19:30 - 21:00

Evandro de Azambuja - NEW
Kevin Punie - NEW
Donatienne Taylor - NEW

Expert panel

Dr. Ana C. Garrido-Castro, MD, Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, Boston, MA

Dr. Evandro de Azambuja, MD, PhD, Jules Bordet Institute, Brussels

Dr. Kevin Punie, MD, Ziekenhuis aan de Stroom, Antwerp

Dr. Donatienne Taylor, MD, Centre Hospitalier Universitaire de l'Université Catholique de Louvain à Namur, Namur 

 

Programme

19:30

Welcome & introduction – Dr. Kevin Punie

19:35

The treatment landscape in mTNBC – Dr. Donatienne Taylor

19:50

mTNBC case discussion – Dr. Kevin Punie & panel

20:15

The treatment landscape in HR+/HER2- mBC – Dr. Evandro de Azambuja

20:30

HR+/HER2- mBC case discussion – Dr. Ana C. Garrido-Castro & panel

20:55

Q&A & Wrap up - Dr. Kevin Punie

 

Learning opportunities

This virtual 90-minute symposium will offer you to:

  1. Discover the unmet needs in earlier lines of mTNBC and HR+/HER2-negative BC and the evolving ADC landscape
  2. Understand the updated ESMO living guidelines in metastatic breast cancer
  3. Recognize ADCs as a treatment option in previously treated triple-negative and HR+/HER2-negative mBC
  4. Learn about effective management of ADC-related AEs across various patient profiles in HER2-negative mBC
  5. Discuss clinical strategies for challenging patient cases

BE-UNB-1564

 

Thanks to

GILEAD